Impact of Statins on Clinical Outcomes After
Objective: We sought to establish the rates of statin use in patients with carotid artery disease and to examine the association between statin therapy and clinical outcomes among an older population after carotid revascularization.
Methods: In this population-level, retrospective cohort study, we identified all individuals $66 years old who underwent carotid endarterectomy or stenting in Ontario, Canada (2002 -2014 . We used the Ontario Drug Benefit database to establish preprocedural and postprocedural statin use and dose on the basis of actual medication prescriptions filled. The primary outcome was a composite of 1-year stroke, myocardial infarction, or death; 5-year outcomes were also assessed. Adjusted hazard ratios (HRs) were computed using inverse probability of treatment weighting based on propensity scores.
Results: A total of 7893 of 10,723 (73.6%) patients who underwent carotid revascularization were receiving preprocedural statin therapy; moderate-or high-dose therapy was used by 7384 (68.9%) patients. The mean (standard deviation) age of patients was 74.7 (5.6) years in the statin group and 75.6 (6.2) years in the nonstatin group (n ¼ 2830); about a third were female, and w45% had symptomatic carotid disease in both groups. The composite rate of 1-year stroke, myocardial infarction, or death was lower among statin users (adjusted HR, 0.76; 95% confidence interval, 0.70-0.83), as was the composite rate at 5 years (adjusted HR, 0.75; 95% confidence interval, 0.71-0.80; Fig 1) . Individual rates of stroke, myocardial infarction, and death were also lower with statin use, and the beneficial associations with statin use were observed regardless of type of carotid revascularization procedure, carotid artery symptom status, or statin dose (Fig 2) .
Conclusions: Statin therapy was associated with a w25% lower risk of cardiovascular events in patients with significant carotid disease. Along with other supportive evidence, statins should be considered in patients undergoing carotid revascularization, and efforts are required to increase statin use in this undertreated population.
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